1urc: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{STRUCTURE_1urc| PDB=1urc | SCENE= }} | {{STRUCTURE_1urc| PDB=1urc | SCENE= }} | ||
===Cyclin A binding groove inhibitor Ace-Arg-Lys-Leu-Phe-Gly=== | |||
{{ABSTRACT_PUBMED_15455144}} | |||
=== | ==Function== | ||
[[http://www.uniprot.org/uniprot/CDK2_HUMAN CDK2_HUMAN]] Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Interacts with cyclins A, B1, B3, D, or E. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in human embryonic stem cells (hESCs). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2 (cyclin A1 in germ cells) during the late stages of DNA replication to drive the transition from S phase to mitosis, the G2 phase. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. Phosphorylates CABLES1 (By similarity). Cyclin E/CDK2 prevents oxidative stress-mediated Ras-induced senescence by phosphorylating MYC. Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis. In response to DNA damage, double-strand break repair by homologous recombination a reduction of CDK2-mediated BRCA2 phosphorylation. Phosphorylation of RB1 disturbs its interaction with E2F1. NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication. Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT-mediated activation of histone gene transcription during S phase. Required for vitamin D-mediated growth inhibition by being itself inactivated. Involved in the nitric oxide- (NO) mediated signaling in a nitrosylation/activation-dependent manner. USP37 is activated by phosphorylation and thus triggers G1-S transition. CTNNB1 phosphorylation regulates insulin internalization.<ref>PMID:10499802</ref> <ref>PMID:11051553</ref> <ref>PMID:10995386</ref> <ref>PMID:10995387</ref> <ref>PMID:10884347</ref> <ref>PMID:11113184</ref> <ref>PMID:15800615</ref> <ref>PMID:18372919</ref> <ref>PMID:20147522</ref> <ref>PMID:20079829</ref> <ref>PMID:20935635</ref> <ref>PMID:20195506</ref> <ref>PMID:19966300</ref> <ref>PMID:21262353</ref> <ref>PMID:21596315</ref> <ref>PMID:21319273</ref> <ref>PMID:17495531</ref> [[http://www.uniprot.org/uniprot/CCNA2_HUMAN CCNA2_HUMAN]] Essential for the control of the cell cycle at the G1/S (start) and the G2/M (mitosis) transitions. | |||
==About this Structure== | ==About this Structure== | ||
| Line 15: | Line 14: | ||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID:015455144</ref><references group="xtra"/> | <ref group="xtra">PMID:015455144</ref><references group="xtra"/><references/> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Andrews, M.]] | [[Category: Andrews, M.]] | ||
[[Category: Cowan, A.]] | [[Category: Cowan, A.]] | ||
| Line 26: | Line 24: | ||
[[Category: Kontopidis, G.]] | [[Category: Kontopidis, G.]] | ||
[[Category: Lane, D.]] | [[Category: Lane, D.]] | ||
[[Category: | [[Category: McInnes, C.]] | ||
[[Category: Paterson, D.]] | [[Category: Paterson, D.]] | ||
[[Category: Plater, A.]] | [[Category: Plater, A.]] | ||
| Line 32: | Line 30: | ||
[[Category: Walkinshaw, M.]] | [[Category: Walkinshaw, M.]] | ||
[[Category: Zheleva, D.]] | [[Category: Zheleva, D.]] | ||
[[Category: Drug design]] | [[Category: Drug design]] | ||
[[Category: Inhibitor]] | [[Category: Inhibitor]] | ||
[[Category: Ligand exchange]] | [[Category: Ligand exchange]] | ||
[[Category: Peptidomimetic]] | [[Category: Peptidomimetic]] | ||
[[Category: Transferase-inhibitor complex]] | |||